Literature DB >> 25763789

Fibroblast growth factor receptor 2 fusions as a target for treating cholangiocarcinoma.

Mitesh J Borad1, Gregory J Gores, Lewis R Roberts.   

Abstract

PURPOSE OF REVIEW: This review will cover the role of the fibroblast growth factor pathway in the pathogenesis, targeted therapy potential and prognostic value in patients with cholangiocarcinoma (CCA). RECENT
FINDINGS: Recent studies that have identified fibroblast growth factor receptor 2 (FGFR2) fusions, prognostic implications of FGFR2 fusions, treatment strategies that target FGFR2 in CCA and future directions for understanding and targeting the FGFR2 pathway in this disease, will be discussed.
SUMMARY: Understanding the role of the FGFR2 pathway as a disease pathogenetic mechanism and the ability to develop targeted therapies and diagnostics surrounding this concept are critical elements toward developing novel targeted approaches in CCA.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25763789      PMCID: PMC4750878          DOI: 10.1097/MOG.0000000000000171

Source DB:  PubMed          Journal:  Curr Opin Gastroenterol        ISSN: 0267-1379            Impact factor:   3.287


  19 in total

1.  Monoclonal antibodies to fibroblast growth factor receptor 2 effectively inhibit growth of gastric tumor xenografts.

Authors:  Wei-meng Zhao; Lihong Wang; Hangil Park; Sophea Chhim; Melanie Tanphanich; Masakazu Yashiro; K Jin Kim
Journal:  Clin Cancer Res       Date:  2010-07-29       Impact factor: 12.531

2.  Fibroblast growth factor receptor 3 (FGFR3) is a strong heat shock protein 90 (Hsp90) client: implications for therapeutic manipulation.

Authors:  Melanie B Laederich; Catherine R Degnin; Gregory P Lunstrum; Paul Holden; William A Horton
Journal:  J Biol Chem       Date:  2011-04-12       Impact factor: 5.157

3.  The driver of malignancy in KG-1a leukemic cells, FGFR1OP2-FGFR1, encodes an HSP90 addicted oncoprotein.

Authors:  Yixin Jin; Yan Zhen; Ellen Margrethe Haugsten; Antoni Wiedlocha
Journal:  Cell Signal       Date:  2011-06-30       Impact factor: 4.315

4.  Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.

Authors:  Juan Valle; Harpreet Wasan; Daniel H Palmer; David Cunningham; Alan Anthoney; Anthony Maraveyas; Srinivasan Madhusudan; Tim Iveson; Sharon Hughes; Stephen P Pereira; Michael Roughton; John Bridgewater
Journal:  N Engl J Med       Date:  2010-04-08       Impact factor: 91.245

5.  FGFR3 translocations in bladder cancer: differential sensitivity to HSP90 inhibition based on drug metabolism.

Authors:  Jaime Acquaviva; Suqin He; Chaohua Zhang; John-Paul Jimenez; Masazumi Nagai; Jim Sang; Manuel Sequeira; Donald L Smith; Luisa Shin Ogawa; Takayo Inoue; Noriaki Tatsuta; Margaret A Knowles; Richard C Bates; David A Proia
Journal:  Mol Cancer Res       Date:  2014-04-30       Impact factor: 5.852

Review 6.  Fibroblast growth factor signalling: from development to cancer.

Authors:  Nicholas Turner; Richard Grose
Journal:  Nat Rev Cancer       Date:  2010-02       Impact factor: 60.716

7.  Combined targeting of FGFR2 and mTOR by ponatinib and ridaforolimus results in synergistic antitumor activity in FGFR2 mutant endometrial cancer models.

Authors:  Joseph M Gozgit; Rachel M Squillace; Matthew J Wongchenko; David Miller; Scott Wardwell; Qurish Mohemmad; Narayana I Narasimhan; Frank Wang; Tim Clackson; Victor M Rivera
Journal:  Cancer Chemother Pharmacol       Date:  2013-03-07       Impact factor: 3.333

8.  Exome sequencing of liver fluke-associated cholangiocarcinoma.

Authors:  Choon Kiat Ong; Chutima Subimerb; Chawalit Pairojkul; Sopit Wongkham; Ioana Cutcutache; Willie Yu; John R McPherson; George E Allen; Cedric Chuan Young Ng; Bernice Huimin Wong; Swe Swe Myint; Vikneswari Rajasegaran; Hong Lee Heng; Anna Gan; Zhi Jiang Zang; Yingting Wu; Jeanie Wu; Ming Hui Lee; DaChuan Huang; Pauline Ong; Waraporn Chan-on; Yun Cao; Chao-Nan Qian; Kiat Hon Lim; Aikseng Ooi; Karl Dykema; Kyle Furge; Veerapol Kukongviriyapan; Banchob Sripa; Chaisiri Wongkham; Puangrat Yongvanit; P Andrew Futreal; Vajarabhongsa Bhudhisawasdi; Steve Rozen; Patrick Tan; Bin Tean Teh
Journal:  Nat Genet       Date:  2012-05-06       Impact factor: 38.330

9.  Fibroblast growth factor receptor 2 translocations in intrahepatic cholangiocarcinoma.

Authors:  Rondell P Graham; Emily G Barr Fritcher; Ekaterina Pestova; John Schulz; Leonid A Sitailo; George Vasmatzis; Stephen J Murphy; Robert R McWilliams; Steven N Hart; Kevin C Halling; Lewis R Roberts; Gregory J Gores; Fergus J Couch; Lizhi Zhang; Mitesh J Borad; Benjamin R Kipp
Journal:  Hum Pathol       Date:  2014-04-13       Impact factor: 3.466

10.  Identification of targetable FGFR gene fusions in diverse cancers.

Authors:  Yi-Mi Wu; Fengyun Su; Shanker Kalyana-Sundaram; Nickolay Khazanov; Bushra Ateeq; Xuhong Cao; Robert J Lonigro; Pankaj Vats; Rui Wang; Su-Fang Lin; Ann-Joy Cheng; Lakshmi P Kunju; Javed Siddiqui; Scott A Tomlins; Peter Wyngaard; Seth Sadis; Sameek Roychowdhury; Maha H Hussain; Felix Y Feng; Mark M Zalupski; Moshe Talpaz; Kenneth J Pienta; Daniel R Rhodes; Dan R Robinson; Arul M Chinnaiyan
Journal:  Cancer Discov       Date:  2013-04-04       Impact factor: 39.397

View more
  19 in total

Review 1.  Targeting cholangiocarcinoma.

Authors:  Joachim C Mertens; Sumera Rizvi; Gregory J Gores
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2017-08-24       Impact factor: 5.187

Review 2.  The rise of the FGFR inhibitor in advanced biliary cancer: the next cover of time magazine?

Authors:  Sumera Rizvi; Mitesh J Borad
Journal:  J Gastrointest Oncol       Date:  2016-10

3.  FGFR Inhibitor Toxicity and Efficacy in Cholangiocarcinoma: Multicenter Single-Institution Cohort Experience.

Authors:  Jennifer J Gile; Fang-Shu Ou; Amit Mahipal; Joseph J Larson; Kabir Mody; Zhaohui Jin; Joleen Hubbard; Thorvardur Halfdanarson; Steven R Alberts; Aminah Jatoi; Robert R McWilliams; Wen Wee Ma; Sumera Ilyas; Rory Smoot; Lewis Roberts; Gregory Gores; Mitesh Borad; Tanios S Bekaii-Saab; Nguyen H Tran
Journal:  JCO Precis Oncol       Date:  2021-07-28

Review 4.  Precision medicine in cholangiocarcinoma.

Authors:  Antonio Pellino; Fotios Loupakis; Massimiliano Cadamuro; Vincenzo Dadduzio; Matteo Fassan; Maria Guido; Umberto Cillo; Stefano Indraccolo; Luca Fabris
Journal:  Transl Gastroenterol Hepatol       Date:  2018-07-12

5.  Antitumor effect of FGFR inhibitors on a novel cholangiocarcinoma patient derived xenograft mouse model endogenously expressing an FGFR2-CCDC6 fusion protein.

Authors:  Yu Wang; Xiwei Ding; Shaoqing Wang; Catherine D Moser; Hassan M Shaleh; Essa A Mohamed; Roongruedee Chaiteerakij; Loretta K Allotey; Gang Chen; Katsuyuki Miyabe; Melissa S McNulty; Albert Ndzengue; Emily G Barr Fritcher; Ryan A Knudson; Patricia T Greipp; Karl J Clark; Michael S Torbenson; Benjamin R Kipp; Jie Zhou; Michael T Barrett; Michael P Gustafson; Steven R Alberts; Mitesh J Borad; Lewis R Roberts
Journal:  Cancer Lett       Date:  2016-05-20       Impact factor: 8.679

6.  Detection of Novel Fusion Transcript VTI1A-CFAP46 in Hepatocellular Carcinoma.

Authors:  Shunichi Tsuge; Behnam Saberi; Yulan Cheng; Zhixiong Wang; Amy Kim; Harry Luu; John M Abraham; Maria D Ybanez; James P Hamilton; Florin M Selaru; Carlos Villacorta-Martin; Felix Schlesinger; Benjamin Philosophe; Andrew M Cameron; Qingfeng Zhu; Robert Anders; Ahmet Gurakar; Stephen J Meltzer
Journal:  Gastrointest Tumors       Date:  2019-04-10

Review 7.  Cholangiocarcinoma: Current Knowledge and New Developments.

Authors:  Boris Blechacz
Journal:  Gut Liver       Date:  2017-01-15       Impact factor: 4.519

Review 8.  IDH1 Targeting as a New Potential Option for Intrahepatic Cholangiocarcinoma Treatment-Current State and Future Perspectives.

Authors:  Fabiana Crispo; Michele Pietrafesa; Valentina Condelli; Francesca Maddalena; Giuseppina Bruno; Annamaria Piscazzi; Alessandro Sgambato; Franca Esposito; Matteo Landriscina
Journal:  Molecules       Date:  2020-08-18       Impact factor: 4.411

9.  Preclinical Activity of ARQ 087, a Novel Inhibitor Targeting FGFR Dysregulation.

Authors:  Terence G Hall; Yi Yu; Sudharshan Eathiraj; Yunxia Wang; Ronald E Savage; Jean-Marc Lapierre; Brian Schwartz; Giovanni Abbadessa
Journal:  PLoS One       Date:  2016-09-14       Impact factor: 3.240

10.  Generation of An Endogenous FGFR2-BICC1 Gene Fusion/58 Megabase Inversion Using Single-Plasmid CRISPR/Cas9 Editing in Biliary Cells.

Authors:  Andreas Reicher; Antoneicka L Harris; Felix Prinz; Tobias Kiesslich; Miaoyan Wei; Rupert Öllinger; Roland Rad; Martin Pichler; Lawrence N Kwong
Journal:  Int J Mol Sci       Date:  2020-04-02       Impact factor: 6.208

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.